NYSE:LLYPharmaceuticals
Eli Lilly Expands Into AI DNA Editing With Profluent Enzyme Deal
Eli Lilly (NYSE:LLY) has entered a multi billion dollar partnership with Profluent to develop AI designed enzymes for genetic medicines.
The collaboration focuses on creating custom enzymes that aim to support more precise and scalable DNA editing for hard to treat diseases.
The deal marks a move by Lilly to broaden its research focus beyond GLP 1 therapies and oncology into AI driven DNA editing therapeutics.
Eli Lilly has built a high profile position in obesity and diabetes treatments...